Sanofi-Aventis, makers of Lantus and Apidra – Enters Device Market
Posted Mar 31 2010 9:18am
Reuters reported this morning that Sanofi-Aventis ( NYSE:SNY ), makers of Lantus (long-acting 24 hour) and Apidra (fast-acting) insulins, will partner in the development, supply and commercialization of diabetes care management products (including blood glucose monitors) with AgaMatrix , a privately held US firm.
AgaMatrix already develops a consumer line of glucose blood monitors called WaveSense built on a number of patented technologies which “employ[s] Dynamic Electrochemistry™ to extract a spectrum of information inaccessible to traditional static electrochemical methods.” The WaveSense website says the specialized technology corrects for common sources of error that make blood glucose measurements inaccurate such as environmental conditions (temperature), number of red blood cells in sample (can lead to inaccurate readings), and user errors. AgaMatrix is confident its technology offers better accuracy than standard BGMs available on the market today.
WaveSense also makes a digital blood glucose logbook available for the iPhone or iPod and available on the iTunes App store.
In a today’s press release, Eric Petreto, Vice President of Device Strategy of the Sanofi-Aventis Global Diabetes Division said, “In building our Global Diabetes Division, our objectives included conducting an exhaustive search for potential partners that have excellent core science, are highly innovative, and have the potential to develop a broad range of products. With AgaMatrix, we’ve found a company that can meet all three objectives in the BGM (Blood Glucose Monitor) category.”